MONTRÉAL, le 20 nov. 2024 /CNW/ - La Compagnie Électrique Lion (NYSE: LEV) (TSX: LEV) (« Lion » ou la « Société »), fabricant de premier plan de véhicules urbains de poids moyen et lourd entièrement électriques, a annoncé aujourd'hui que le personnel du NYSE Regulation de la Bourse de New York (« NYSE ») a décidé d'entamer des procédures pour retirer de la cote de la NYSE les bons de souscription de la Société dont la date d'expiration tombe le 6 mai 2026 - symbole boursier LEV.WS - permettant d'acquérir des actions ordinaires de la Société. La négociation des bons de souscription a été suspendue immédiatement. La négociation des ...

Trading Symbol: TSX: SVM                              NYSE AMERICAN: SVM VANCOUVER, BC, Nov. 19, 2024 /CNW/ - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM) today announced that it has commenced a private placement offering of US$130,000,000 aggregate principal amount of convertible senior notes due 2029 (the "Notes" and the "Offering"). The Company intends to grant the initial purchasers of the Notes an option to purchase up to an additional US$20,000,000 aggregate principal amount of Notes, exercisable in whole or in part at any time until ...

NEW YORK, Nov. 20, 2024 /CNW/ - Galaxy Digital Holdings Ltd. (TSX: GLXY) ("GDH Ltd." or the "Company") is pleased to announce that Galaxy Digital Holdings LP (the "Issuer," and together with GDH Ltd., "Galaxy") has priced its offering of $350 million (upsized from previously announced $300 million) aggregate principal amount of 2.50% exchangeable senior notes due 2029 (the "Notes"). The Issuer intends to use the net proceeds from the offering to support the build-out of high-performance computing infrastructure at its Helios data center in West Texas and for general corporate purposes, including potential repurchases of its existing indebtedness.

DiffuSphere™ is designed to enable precise drug delivery at therapeutic dose levels directly into target tissues, enhancing efficacy while minimizing systemic drug levels to optimize safetyIn clinical trials, a single administration of DiffuSphere™ successfully delivered fluticasone propionate for at least six months in patients with eosinophilic esophagitis or osteoarthritisDiffuSphere™ has shown its versatility with various drug classes, supporting the possibility to treat multiple types of pain, infectious diseases, eye diseases and cancersVICTORIA, BC, Nov. 20, 2024 /CNW/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ: EPRX) (TSX: EPRX), a clinical-stage biotechnology company, today unveiled new pharmacokinetic ("PK") data from its Phase ...